Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its earnings results on Monday, March 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03, Briefing.com reports. The company had revenue of $60.40 million during the quarter, compared to analysts’ expectations of $60.62 million. Amphastar Pharmaceuticals had a net margin of 1.88% and a return on equity of 4.56%. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.01 earnings per share.
AMPH stock traded up $0.12 on Thursday, hitting $19.14. 146,737 shares of the company were exchanged, compared to its average volume of 204,712. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.85 and a current ratio of 2.79. Amphastar Pharmaceuticals has a twelve month low of $13.15 and a twelve month high of $20.45. The firm has a market capitalization of $863.97, a price-to-earnings ratio of 50.37, a price-to-earnings-growth ratio of 1.33 and a beta of 1.42.
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 19,801 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total transaction of $398,000.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jason B. Shandell sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total transaction of $388,600.00. Following the sale, the insider now owns 251,372 shares of the company’s stock, valued at $4,884,157.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,387 shares of company stock valued at $1,659,763. 11.10% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/2018/04/05/amphastar-pharmaceuticals-amph-posts-earnings-results/2028935.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.